title: Platelet response as the basis for approval in chronic immune (idiopathic) thrombocytopenic purpura (ITP): a regulatory perspective.
authors.affiliation: European Medicines Agency, London, United Kingdom. francesco.pignatti@ema.europa.eu
authors.forename: Francesco
authors.initials: F
authors.lastname: Pignatti
authors.forename: Beatriz
authors.initials: B
authors.lastname: Flores
authors.forename: Bertil
authors.initials: B
authors.lastname: Jonsson
mesh_terms: D001565:Benzoates / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data*; D006470:Hemorrhage / Q000517:prevention & control*; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use*; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000188:drug therapy*; D011720:Pyrazoles / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data*; D011961:Receptors, Fc / Q000627:therapeutic use*; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*; D013926:Thrombopoietin / Q000819:agonists* / Q000627:therapeutic use
chemical_list: D001565:Benzoates; D006834:Hydrazines; D011720:Pyrazoles; D011961:Receptors, Fc; D011993:Recombinant Fusion Proteins; D013926:Thrombopoietin; C488777:romiplostim; C520809:eltrombopag